Medical data platform company JNPMEDI (CEO Kwunho Jeong) announced that it will host the 'Maven Safety Launch Webinar' on the 19th, showcasing its new drug safety management solution, Maven Safety.
In this webinar, JNPMEDI will introduce the new product Maven Safety and share insights and information on regulatory reporting following the E2B(R3) guidelines.
In the first session, Seungbum Yang, the Product Owner (PO) who led the planning of Maven Safety at JNPMEDI, will present on 'The Need for Safety DB Management' and will provide a live demo of the Maven Safety solution.
In the second session, Minjeong Lim, CEO of Medisafe, will give a presentation on 'The Distinctive Features of Adverse Drug Reaction Reporting and Management Using Maven Safety.'
Following the sessions, a networking opportunity will be provided where industry professionals participating in the webinar can discuss current issues regarding mandatory regulatory reporting.
JNPMEDI CEO Kwunho Jeong stated, "At this pivotal moment where the paradigm of clinical trials is changing due to the advent of innovative digital technologies, JNPMEDI will continue to strive for technological development to advance the digitization of clinical trials and the bio-industry."
Anyone in the industry can register to participate in the webinar on the 19th, and more details are available on the official JNPMEDI website.
Medical data platform company JNPMEDI (CEO Kwunho Jeong) announced that it will host the 'Maven Safety Launch Webinar' on the 19th, showcasing its new drug safety management solution, Maven Safety.
In this webinar, JNPMEDI will introduce the new product Maven Safety and share insights and information on regulatory reporting following the E2B(R3) guidelines.
In the first session, Seungbum Yang, the Product Owner (PO) who led the planning of Maven Safety at JNPMEDI, will present on 'The Need for Safety DB Management' and will provide a live demo of the Maven Safety solution.
In the second session, Minjeong Lim, CEO of Medisafe, will give a presentation on 'The Distinctive Features of Adverse Drug Reaction Reporting and Management Using Maven Safety.'
Following the sessions, a networking opportunity will be provided where industry professionals participating in the webinar can discuss current issues regarding mandatory regulatory reporting.
JNPMEDI CEO Kwunho Jeong stated, "At this pivotal moment where the paradigm of clinical trials is changing due to the advent of innovative digital technologies, JNPMEDI will continue to strive for technological development to advance the digitization of clinical trials and the bio-industry."
Anyone in the industry can register to participate in the webinar on the 19th, and more details are available on the official JNPMEDI website.